Business Wire

PA-COHESIVE-COMP/OXPLUS

5.10.2021 22:03:10 CEST | Business Wire | Press release

Share
The Cohesive Companies Expand in Transportation Infrastructure Globally with Acquisition of OXplus and through Executive Succession

The Cohesive Companies, a wholly-owned but independently operated digital integrator business unit of Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced its acquisition of OXplus, the leading rail asset management specialist headquartered in Veghel, Netherlands. The acquisition coincides with the appointment of Dr. Mark Bew MBE as CEO of The Cohesive Companies, succeeding Noah Eckhouse, who has retired after 17 years of exemplary service within Bentley Systems capped by the successful convergence, from multiple predecessor organizations, of The Cohesive Companies in 2020. OXplus becomes the sixth brand to enter The Cohesive Companies fold in support of its mission to deliver the strongest social, economic, and environmental outcomes for infrastructure clients and their constituents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005250/en/

OXplus supports rail owners, operators, and maintainers, and rolling stock manufacturers around the globe with digital tools and solutions that give them a deep insight into the performance of their assets. It builds smart systems, and delivers standout client experiences, that use IoT data to effectively predict when repair or intervention is needed, that prevent downtime, that reduce operational costs, and that enable efficient scheduling of assets. The acquisition of OXplus, founded in 2010, will accelerate The Cohesive Companies’ expansion of its Enterprise Asset Management presence within Europe and elsewhere. For instance, OXplus has recently supported the prestigious Riyadh Metro project, the largest single-phase metro project underway globally, and is also supporting Siemens Mobility to efficiently execute the maintenance of Riyadh Metro’s new train fleet.

Bew joined Bentley Systems and The Cohesive Companies with its 2020 acquisition of the UK-based built-environment consultancy PCSG, providing digital advisory services and solutions to world-leading owners and operators in the transportation sector. Representative clients and projects include HS2, Europe’s largest infrastructure project, in developing a digital twin of the entire rail system; Highways England (National Highways), operator of the UK strategic road network; and Heathrow Airport Ltd. Prior to his co-leadership of PCSG, Bew held information and business system leadership roles with Costain and URS-Scott Wilson. Based in London, Bew also chaired the UK government’s BIM Task Group, which led the work to embed digital techniques and processes within major UK public sector infrastructure programs.

In a further appointment, George Church has been named COO of The Cohesive Companies. Based in Boston, USA, Church brings a depth of knowledge and expertise gained through 27 years at Bentley Systems, including as senior vice president of its professional services business.

Mark Bew said, “We are delighted to welcome the OXplus team to enhance The Cohesive Companies’ balance across geographies and sectors. Our collective success and learning curves in delivering projects while working fully virtually throughout the pandemic has proven our growth strategy in globally bringing together and further attracting world-class talent resources. I take the helm from Noah Eckhouse enthusiastic about our unique strengths as a full lifecycle digital integrator, delivering transformational outcomes across the built and natural environment, independent of our clients’ investment choices among technology vendors. It is particularly meaningful to me that OXplus’ proficiencies in rail and transport operations and service optimization now helps us be able to fulfill the vision, expressed through the UK public sector’s digital twin aspirations, for improved social benefits from infrastructure.”

OXplus CEO Henri Snijders said, “We are excited that OXplus is joining The Cohesive Companies to strengthen our position as a leading digital consultancy in the railways and transportation sectors. I would like to thank all the team at OXplus for their work and dedication in making this milestone possible.”

Richard Van Dongen, OXplus CCO, added, “Advancements in going digital are driving improvements on major railways projects leading toward the breakthrough advantages of infrastructure and of rolling stock digital twins. We know that together, we can deliver even more operational value for the transportation sector.”

##

About The Cohesive Companies

The Cohesive Companies form a wholly owned but independently operated business unit of Bentley Systems (Nasdaq:BSY, the infrastructure engineering software company www.bentley.com ). The Cohesive Companies provide advisory, systems integration, and technology strategies and services to help owner-operators advance their BIM, enterprise asset management (EAM), asset lifecycle information (ALIM), and asset performance modeling environments. Our uniquely comprehensive expertise in infrastructure digital twins spans from development platforms to operational systems, from cloud to mobile, from asset delivery to customer service optimization, and beyond resourceful technology implementation to change management and business process redesign. The Cohesive Companies have coalesced and globally multiplied the reach and capabilities of Cohesive Solutions, Cohesive Asset Performance, SRO Solutions, PCSG, Ontracks Consulting, and OXplus. www.cohesivecompanies.com

© 2021 Bentley Systems, Incorporated. Bentley, Cohesive Solutions, Cohesive Asset Performance, Ontracks, OXplus, PCSG, SRO Solutions, and The Cohesive Companies are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye